Advertisement

Critical role of NQO1 in ovarian cell injury: highly risk of ovarian carcinoma

 

 
crossMark
 
Pathophysiology of Cell Injury Journal  Volume 1, Issue 1, pages 1-9 December 2012

Yu-Lin Yang, Yongzhang Wang, Junying Shyu, Nan Zhang 

Abstract

Chronic inflammation suppresses NAD(P)H quinone oxidoreductase1 (NQO1) expression and may increase susceptibility to cell injury. Paradoxically, increasing evidence suggests that high expression of NQO1 at the early stages of carcinogenesis may provide cancer cells with a growth advantage. NQO1 was shown to be expressed at high levels in many solid tumors, and to date, the role of NQO1 in ovarian carcinoma remains unclear. In the present study, we investigated the role high expression of NQO1 in ovarian carcinoma. NQO1 protein expression was assessed using RT-PCR, and Western blotting in the human ovarian cancer cell lines. Our results indicate that ovarian carcinoma positively correlated with the expression and activity of NQO1 cells.

Keywords: NQO1; Ovarian carcinoma; Chronic inflammation; Cell injury

Full Text-PDFReferences

 


Choose an option to access this article:
1. Purchase this article at rate $55.00 and received Full-Text/PDF
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use.
2. Full-Text/PDF access through your institution subscription password:

References

 

1. Tan XL, Marquardt G, Massimi AB, et al. High-throughput library screening identifies two novel NQO1 inducers in human lung cells. Am J Respir Cell Mol Biol 2011; 46: 365–371. [PubMed]

2. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathol 2011;43(5):420-32. [Abstract/ Full -Text]

3. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med 2000;29:246-53. [PubMed]

4. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353):609-15. [Abstract/Full-text]

5. Terai K, Dong GZ, Oh ET, et al. Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1. Anticancer Drugs 2009; 20: 901–909. [PubMed]

6. Reinicke KE, Bey EA, Bentle MS, et al. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res 2005;11: 3055–3064. [PubMed]

7. Langdon SP, Lawrie SS, Hay FG, et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988; 48(21):6166-72. [PubMed]

8. Dong GZ, Youn H, Park MT, et al. Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilisation of NQO1 protein. Int J Hyperthermia 2009;25: 477–487. [PubMed]

9. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 1991; 42: 1021–1027. [PubMed]

10. Lin X, Yang H, Zhou L, Guo Z. Nrf2-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med 2011;51: 97–106. [PubMed]

11. Goode EL, White KL, Vierkant RA, et al. Xenobiotic-metabolizing gene polymorphisms and Ovarian cancer risk. Mol Carcinog 2011; 50(5):397-402. [PubMed]

12. Reigan P, Colucci MA, Siegel D, et al. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry 2007; 46:5941-50. [PubMed]

13. Iskander K, Gaikwad A, Paquet M, et al. Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res 2005; 65:2054-8. [PubMed]

14. Awadallah NS, Dehn D, Shah RJ,  et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol 2008;16(1):24-31. [PubMed]

15. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DTdiaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382:115-44. [PubMed]

16. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H: quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origan. Biochem Pharmacol 1991; 42:1021-7. [PubMed]

17. Prawan A, Buranrat B, Kukongviriyapan U, Sripa B, Kukongviriyapan V. Inflammatory cytokines suppress NAD(P)H:quinone oxidoreductase-1 and induce oxidative stress in cholangiocarcinoma cells. J Cancer Res Clin Oncol 2009; 135:515-22. [PubMed]

18. Zhu H1, Jia Z, Mahaney J, et al. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger. Cardiovasc Toxicol 2007; 7(3):202-11. [PubMed]

19. Jaiswal AK. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radical Biology and Medicine 2000;29:254-262. [PubMed]

20. Marchand A, Barouki R, Garlatti M. Regulation of NAD(P)H:quinone oxidoreductase 1 gene expression by CYP1A1 activity. Mol Pharmacol 2004;65(4):1029-37. [PubMed]

21. Jaiswal AK. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 1991;30:10647-10653.

 

Print Friendly
PathoPhysiology of Cell Injury Journal© 2017 BM-Publisher
%d bloggers like this: